Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
- Conditions
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 450
- Registration Number
- NCT06339008
- Locations
- 🇺🇸
Florida Center For Allergy & Asthma Care Aventura, Aventura, Florida, United States
🇺🇸AARA Research Center, Dallas, Texas, United States
🇺🇸Kerrville Allergy and Asthma Associates, Kerrville, Texas, United States
A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
- Conditions
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 510
- Registration Number
- NCT06338995
- Locations
- 🇺🇸
Treasure Valley Medical Research, Boise, Idaho, United States
🇧🇬Diagnostic-Consultative Centre Ascendent EOOD, Sofia, Bulgaria
🇧🇬Multiprofile Hospital for Active treatment Trakia EOOD, Zagora, Bulgaria
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 74
- Registration Number
- NCT06313528
- Locations
- 🇺🇸
AdventHealth Orlando, Orlando, Florida, United States
🇺🇸Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 320
- Registration Number
- NCT06297603
- Locations
- 🇧🇷
IBPClin - Instituto Brasil de Pesquisa Clínica, Rio de Janeiro, Brazil
🇺🇸Diabetes & Endocrine Treatment Specialists, Sandy, Utah, United States
🇦🇷CEDIC, Caba, Buenos Aires, Argentina
A Study of LY3841136 in Japanese Participants With Obesity or Overweight
- Conditions
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT06297616
- Locations
- 🇯🇵
Sumida Hospital, Sumida-ku, Tokyo, Japan
🇯🇵Hakata Clinic, Fukuoka, Japan
🇯🇵P-One Clinic, Hachioji, Tokyo, Japan
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT06297590
- Locations
- 🇺🇸
K2 Medical Research, LLC, Maitland, Florida, United States
🇺🇸Charter Research, LLC, The Villages, Florida, United States
🇺🇸CenExel iResearch, LLC (CenExel iRA), Decatur, Georgia, United States
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 12500
- Registration Number
- NCT06292013
- Locations
- 🇺🇸
MedStar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸Clearwater Cardiovascular & Interventional Consultants M.D., P.A., Safety Harbor, Florida, United States
🇺🇸Clinical Research of West Florida, Inc. (Clearwater), Clearwater, Florida, United States
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT06280703
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 430
- Registration Number
- NCT06280716
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan-si, Kyǒnggi-do, Korea, Republic of
🇰🇷National Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1250
- Registration Number
- NCT06260722
- Locations
- 🇺🇸
Rocky Mountain Clinical Research, Idaho Falls, Idaho, United States
🇺🇸Deaconess Clinic - Gateway Health Center, Newburgh, Indiana, United States
🇺🇸IMA Clinical Research Monroe - Armand, Monroe, Louisiana, United States